NEPHRIX Biosolutions – Your kidney diseases preclinical research partner
Chronic kidney disease (CKD) affects over 850 million people worldwide, yet the translation gap between preclinical research and clinical outcomes remains a critical obstacle for drug developers. NEPHRIX Biosolutions is a dedicated renal CRO founded to bridge this gap, providing pharma and biotech companies with highly translational, kidney-specific preclinical services that faithfully reflect human CKD pathophysiology.
Whether you are developing a new therapeutic candidate for fibrosis, inflammation, diabetic nephropathy, or AKI-to-CKD progression, our team delivers the preclinical data packages you need to advance your program with confidence.
Why Choose a Specialized CKD CRO?
Renal drug development requires deep expertise in kidney biology, validated CKD models, and rigorous endpoint quantification. A general-purpose CRO often lacks the organ-specific knowledge to design studies that translate to clinical success. NEPHRIX Biosolutions focuses exclusively on kidney disease, ensuring:
- Scientifically validated kidney models (in vitro and in vivo)
- Experienced renal biologists with hands-on model expertise
- Standardized, reproducible protocols aligned with regulatory expectations
- Integrated histology, biomarker, and molecular biology readouts
Integrated Preclinical CRO Infrastructure
NEPHRIX Biosolutions operates within PROLOGUE BIOTECH, a biotech business incubator, with close access to state-of-the-art imaging and molecular facilities at Université Paul Sabatier (Toulouse III). All R&D activities are performed in independent, dedicated areas with secured access. Our facilities include:
- SPF animal housing facility (200 m²): quarantine + functional evaluation areas
- Cell culture laboratories
- Molecular biology and biochemistry laboratories
- Histology plateform
- Biospecimen storage (-80°C, -150°C, liquid nitrogen)
- Secured data archives
Frequently Asked Questions - Kidney Preclinical Research Services
We run a full panel of validated rodent CKD models including UUO, adenine diet, STZ-induced diabetic nephropathy, IRI, IgA nephropathy, and cisplatin-induced AKI. All models are supported by histological, biochemical, and molecular biology endpoints.
Yes. We work with sponsors from study design through final report, adapting endpoints and readouts to your compound’s mechanism of action and regulatory requirements.
We work primarily with rats and mice. Model and strain selection is made collaboratively based on the disease indication and scientific rationale.
Yes. Our integrated biomarker services cover plasma and urinary markers of kidney function and injury (creatinine, BUN, KIM-1, NGAL, and others), alongside histological scoring and gene expression analysis.